九州通品牌怎么样 申请店铺

我要投票 九州通在减肥药行业中的票数:287 更新时间:2025-02-24
九州通是哪个国家的品牌?「九州通」是 九州通医药集团股份有限公司 旗下著名品牌。该品牌发源于湖北,由创始人刘宝林在2000期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力九州通品牌出海!通过在本页面挂载九州通品牌的产品链接和联系邮箱,可以提高九州通产品曝光!跨境电商爆单神器,目前只要100元/年哦~

九州通怎么样

九州通医药集团股份有限公司是一家以药品、医疗器械、生物制品、保健品等产品批发、零售连锁、药品生产与研发及有关增值服务为核心业务的大型企业集团。

截至2012年12月31日,九州通医药集团拥有总资产148.04亿元,员工9,148人,下属公司80余家,直营和加盟的零售连锁药店875家。2012年,九州通医药集团实现营业收入295.08亿元,上缴税收近5亿元。

九州通医药集团拥有完善的品种结构和丰富的客户资源,经营品规达160,000多个,上游供货商5,600家,下游客户70,000多家,取得了国内131种药品的全国或区域总经销或总代理资格。至今为止,九州通医药集团已在全国22个省会城市设立了22家省级子公司(大型医药物流中心)、在29个地级市设立了29家地级公司(地区医药物流配送中心)及400多个终端配送点,形成了覆盖全国大部分县级行政区域的物流配送网络。

打造企业核心竞争力,九州通医药集团秉持“技术让服务更卓越”的理念,致力于现代物流技术和信息技术的开发和应用。目前,九州通医药集团是国内唯一具备独立整合物流规划、物流实施、系统集成能力的医药分销企业,并取得了20多项自主知识产权,在现代物流技术和信息技术方面处于国内领先、国际一流的地位,是国内医药行业唯一获得“中国物流改革开放30年旗帜企业”称号的企业。

九州通医药集团具备向上下游客户提供需求解决方案及增值服务的能力,并逐渐将技术增值服务延伸到了上下游产业链,形成了独具特色的物流管理、供应链管理、医院管理三大产品线,可以满足客户对技术的最高要求。

近年来,九州通医药集团曾获得“国家5A级物流企业”、“湖北省最具影响力民营企业”、“湖北省守合同重信用企业”、“中国社会责任感优秀企业”、“全国非公有制企业双强百佳党组织”等多项荣誉。

未来,九州通医药集团将顺应医药市场变革,继续坚持以医药分销为核心业务,以医院纯销、中药材、医疗器械、零售连锁为战略业务,以物流技术营销、电子商务、国际贸易、原料药等为新兴业务的业务组合战略;扩大和完善医药营销网络布局,不断为医药健康产业提供高性价比服务,努力将九州通打造成为中国医药健康产业最佳服务商。

JIUZHOUTONG Pharmaceutical Group Co., Ltd. is a large-scale enterprise group with the core business of wholesale, retail chain, drug production and R & D and related value-added services of drugs, medical devices, biological products, health products and other products. As of December 31, 2012, JIUZHOUTONG Pharmaceutical Group has a total assets of 14.804 billion yuan, 9148 employees, more than 80 subordinate companies, 875 retail chain drugstores directly operated and joined. In 2012, JIUZHOUTONG Pharmaceutical Group achieved an operating revenue of 29.508 billion yuan and turned in tax revenue of nearly 500 million yuan. JIUZHOUTONG Pharmaceutical Group has a complete variety structure and rich customer resources. It operates more than 160000 products, 5600 upstream suppliers and 70000 downstream customers. It has obtained the qualification of national or regional general distribution or general agent of 131 kinds of drugs in China. So far, JIUZHOUTONG Pharmaceutical Group has set up 22 provincial subsidiaries (large pharmaceutical logistics centers) in 22 provincial capitals, 29 prefecture level companies (regional pharmaceutical logistics distribution centers) and more than 400 terminal distribution points in 29 prefecture level cities, forming a logistics distribution network covering most county-level administrative regions of the country. To build the core competitiveness of the enterprise, JIUZHOUTONG Pharmaceutical Group adheres to the concept of "technology makes service more excellent", and is committed to the development and application of modern logistics technology and information technology. At present, JIUZHOUTONG Pharmaceutical Group is the only pharmaceutical distribution enterprise in China that has the ability to independently integrate logistics planning, logistics implementation and system integration, and has obtained more than 20 independent intellectual property rights. It is in the leading position in modern logistics technology and information technology in China and the first-class position in the world. It is the only one in the domestic pharmaceutical industry that has won the title of "30 years banner enterprise of China's logistics reform and opening up" Enterprises. JIUZHOUTONG Pharmaceutical Group has the ability to provide demand solutions and value-added services to upstream and downstream customers, and gradually extends technology value-added services to the upstream and downstream industrial chains, forming a unique logistics management, supply chain management, hospital management three product lines, which can meet the highest requirements of customers for technology. In recent years, JIUZHOUTONG Pharmaceutical Group has won many honors, such as "national 5A level logistics enterprise", "the most influential private enterprise in Hubei Province", "Hubei Province contract abiding and trustworthy enterprise", "China's outstanding enterprise of social responsibility", "national top 100 Party organizations of non-public enterprises". In the future, JIUZHOUTONG Pharmaceutical Group will continue to adhere to the core business of pharmaceutical distribution, the strategic business of hospital pure sales, Chinese herbal medicine, medical devices, retail chain, the business combination strategy of logistics technology marketing, e-commerce, international trade, API and other emerging businesses, expand and improve the layout of pharmaceutical marketing network, and continue to serve the medical health The industry provides cost-effective services and strives to build Jiuzhoutong into the best service provider in China's pharmaceutical and health industry.

本文链接: https://brand.waitui.com/02808d9a5.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

一汽大众ID.系列部分车型官降至高5.5万元

一汽-大众宣布对旗下ID.系列部分车型进行降价,最高降幅达5.5万元。此次降价活动涉及ID.4 CROZZ和ID.6 CROZZ两款车型,无门槛一口价分别为13.99万元和19.59万元起,还可叠加官方置换补贴至高1万元、国家置换补贴至高2万元。(财联社)

43分钟前

2025年中央一号文件发布

36氪获悉,2025年中央一号文件2月23日发布,《中共中央 国务院关于进一步深化农村改革 扎实推进乡村全面振兴的意见》提出,以改革开放和科技创新为动力,巩固和完善农村基本经营制度,深入学习运用“千万工程”经验,确保国家粮食安全,确保不发生规模性返贫致贫,提升乡村产业发展水平、乡村建设水平、乡村治理水平,千方百计推动农业增效益、农村增活力、农民增收入,为推进中国式现代化提供基础支撑,这是党的十八大以来第13个指导“三农”工作的中央一号文件。

43分钟前

海天味业:公司发行H股备案申请材料获中国证监会接收

36氪获悉,海天味业公告称,公司已于2025年1月13日向香港联交所递交了发行H股股票并在香港联交所主板挂牌上市的申请。公司已向中国证监会报送了关于公司本次发行的备案申请材料并于近日获中国证监会接收。该事项仍存在不确定性,公司将根据进展情况及时履行信息披露义务。

43分钟前

山河药辅:股东复星医药拟减持不超过3%公司股份

36氪获悉,山河药辅发布公告,股东上海复星医药产业发展有限公司因经营需要,计划以集中竞价和大宗交易方式合计减持公司股份不超过697.8万股,即不超过公司总股本的3%。

43分钟前

镁伽科技正式推出LABILLION™实验室智慧管理平台,并于线上发布

36氪获悉,近日镁伽科技正式推出LABILLION™实验室智慧管理平台,并于线上发布。作为镁伽在“AI for Science(AI4S)”领域的新成果,LABILLION™以AI与自动化技术为核心,针对生命科学研发中长期存在的数据孤岛、系统僵化、流程低效等痛点,为科学家提供从实验设计到数据分析的全链路智能支持,助力科研创新效率的提升。

43分钟前

本页详细列出关于泰尔维亭的品牌信息,含品牌所属公司介绍,泰尔维亭所处行业的品牌地位及优势。
咨询